Dyslipidaemia in type 2 diabetes mellitus: Bad for the heart

Current Opinion in Cardiology

Volumn 32, Issue 4, 2017, Pages 422-429

  Katsiki, Niki ^a   Tentolouris, Nikolaos ^b   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

antidiabetic drugs; antihypertensive drugs; coronary heart disease; diabetic dyslipidaemia; hypolipidaemic drugs; postprandial lipaemia; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY RISK; DIABETIC COMPLICATION; DIABETIC DYSLIPIDEMIA; DIABETIC PATIENT; DRUG EFFICACY; DYSLIPIDEMIA; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; CORONARY ARTERY DISEASE; HYPERLIPIDEMIA; METABOLISM; TREATMENT OUTCOME;

CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 85016618588     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000407     Document Type: Review

References (160)

1. Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: recent treatment strategies and future perspectives. World J Cardiol 2015; 7:119-124.
2. Lathief S, Inzucchi SE. Approach to diabetes management in patients with CVD. Trends Cardiovasc Med 2016; 26:165-179.
3. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127:143-152.
4. Lee C, Joseph L, Colosimo A, Dasgupta K. Mortality in diabetes compared with previous cardiovascular disease: a gender-specific meta-analysis. Dia-betes Metab 2012; 38:420-427.
5. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73-78.
6. Savonitto S, Morici N, Cavallini C, et al. One-year mortality in elderly adults with non-ST-elevation acute coronary syndrome: effect of diabetic status and admission hyperglycemia. J Am Geriatr Soc 2014; 62:1297-1303.
7. Radomska E, Sadowski M, Kurzawski J, et al. ST-segment elevation myo-cardial infarction in women with type 2 diabetes. Diabetes Care 2013; 36:3469-3475.
8. Rousan TA, Pappy RM, Chen AY, et al. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). Am J Cardiol 2014; 114:1136-1144.
9. Ahmadi A, Soori H, Sajjadi H. Modeling of in hospital mortality determinants in myocardial infarction patients, with and without type 2 diabetes, undergoing pharmaco-invasive strategy: the first national report using two approaches in Iran. Diabetes Res Clin Pract 2015; 108:216-222.
10. Li N, Yang YG, Chen MH. Comparing the adverse clinical outcomes in patients with noninsulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016; 16:238.
11. Sobel BE. Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial. Coron Artery Dis 2010; 21:189-198.
12. Hee L, Mussap CJ, Yang L, et al. Outcomes of coronary revascularization (percutaneous or bypass) in patients with diabetes mellitus and multivessel coronary disease. Am J Cardiol 2012; 110:643-648.
13. Zhang Q, Liu T, Ng CY, Li G. Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies. Cardiovasc Ther 2014; 32:233-2341.
14. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108:56-62.
15. Siscovick DS, Sotoodehnia N, Rea TD, et al. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord 2010; 11:53-59.
16. King RJ, Grant PJ. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz 2016; 41:184-192.
17. Masmiquel L, Leiter LA, Vidal J, et al. LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol 2016; 15:29.
18. Blomster JI, Woodward M, Zoungas S, et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open 2016; 6:e009668.
19. Cusi K. Treatment of patients with type 2 diabetes and nonalcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016; 59:1112-1120.
20. Papademetriou V, Lovato L, Doumas M, et al. ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovas-cular risk in patients with type 2 diabetes. Kidney Int 2015; 87:649-659.
21. Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: is there a link? Curr Pharm Des 2013; 19:4930-4937.
22. Szalat A, Durst R, Leitersdorf E. Managing dyslipidaemia in type 2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2016; 30:431-444.
23. Sone H, Tanaka S, Tanaka S, et al. Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011; 96:3448-3456.
24. Pereira EC, Bertolami MC, Faludi AA, et al. Predictive potential of twenty-two biochemical biomarkers for coronary artery disease in type 2 diabetes mellitus. Int J Endocrinol 2015; 2015:146816.
25. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002; 90 (8A):55i-61i.
26. Raffield LM, Hsu FC, Cox AJ, et al. Predictors of all-cause and cardiovascular disease mortality in type 2 diabetes: Diabetes Heart Study. Diabetol Metab Syndr 2015; 7:58.
27. Park GM, An H, Lee SW, et al. Risk score model for the assessment of coronary artery disease in asymptomatic patients with type 2 diabetes. Medicine (Baltimore) 2015; 94:e508.
28. Fujihara K, Suzuki H, Sato A, et al. Carotid artery plaque and LDL-to-HDL cholesterol ratio predict atherosclerotic status in coronary arteries in asymptomatic patients with type 2 diabetes mellitus. J Atheroscler Thromb 2013; 20:452-464.
29. Eliasson B, Cederholm J, Eeg-Olofsson K, et al., National Diabetes Register. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care 2011; 34:2095-2100.
30. Pres D, Gasior M, Lekston A, et al. Relationship between low-density lipoprotein cholesterol level on admission and in-hospital mortality in patients with ST-segment elevation myocardial infarction, with or without diabetes, treated with percutaneous coronary intervention. Kardiol Pol 2010; 68:1005-1012.
31. Zeng RX, Li XL, Zhang MZ, et al. Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes. Atherosclerosis 2014; 237:536-543.
32. Sukhija R, Aronow WS, Sureddi R, et al. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol 2007; 100:777-780.
33. Qin Z, Zheng F, Zeng C, et al. Elevated very low density lipoprotein cholesterol levels are independently associated with in-stent restenosis in diabetic patients after drug-eluting stent implantation. Angiology 2017; In press.
34. Valensi P, Avignon A, Sultan A, et al. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol 2016; 15:104.
35. Prenner SB, Mulvey CK, Ferguson JF, et al. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis 2014; 236:244-250.
36. Kasteleyn MJ, Vos RC, Jansen H, Rutten GE. Differences in clinical characteristics between patients with and without type 2 diabetes hospitalized with a first myocardial infarction. J Diabetes Complications 2016; 30:830-833.
37. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, ather-ogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9:531-532.
38. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, ather-ogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9:533-571.
39. Berneis K, Jeanneret C, Muser J, et al. Low-density lipoprotein size and subclasses are markers of clinically apparent and nonapparent atherosclerosis in type 2 diabetes. Metabolism 2005; 54:227-234.
40. Huang YC, Chang PY, Hwang JS, Ning HC. Association of small dense low density lipoprotein cholesterol in type 2 diabetics with coronary artery disease. Biomed J 2014; 37:375-379.
41. Rizzo M, Al-Busaidi N, Rizvi AA. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opin Pharmacother 2015; 16:281-284.
42. Katsiki N, Athyros VG, Karagiannis A. Achieving lipid targets in primary care settings. Curr Med Res Opin 2014; 30:1971-1974.
43. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of nonfasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9:258-270.
44. Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011; 9:292-301.
45. Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, et al. Assessment of postprandial triglycerides in clinical practice: validation in a general population and coronary heart disease patients. J Clin Lipidol 2016; 10:1163-1171.
46. Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin 2014; 30:1489-1503.
47. Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J 2015; 39:353-362.
48. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Dia-betologia 2015; 58:886-899.
49. Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21:178-185.
50. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51:314-324.
51. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12:627-641.
52. Van Linthout S, Spillmann F, Schultheiss HP, Tschöpe C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des 2010; 16:1504-1516.
53. Kostapanos MS, Elisaf MS. High density lipoproteins and type 2 diabetes: emerging concepts in their relationship. World J Exp Med 2014; 4:1-6.
54. Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients withtype 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2016; 23:150-156.
55. Esteghamati A, Asnafi S, Eslamian M, et al. Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. Endocr Res 2015; 40:14-19.
56. Sánchez-Quesada JL, Vinagre I, de Juan-Franco E, et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-as-sociated phospholipase A2 distribution. Am J Cardiol 2012; 110:67-71.
57. Gomez Rosso L, Lhomme M, Meroño T, et al. Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. Biochim Biophys Acta 2017; 1862:188-195.
58. Manfredini F, D'Addato S, Laghi L, et al. Influence of lifestyle measures on hypertriglyceridaemia. Curr Drug Targets 2009; 10:344-355.
59. Del Pilar Solano M, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am 2005; 34:1-25.
60. Athyros VG, Katsiki N, Doumas M, et al. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013; 29:1263-1274.
61. Kalyvas AV, Vlachos K, Abu-Amara M, et al. Bariatric surgery as metabolic surgery for diabetic patients. Curr Pharm Des 2014; 20:3631-3646.
62. Filippatos TD, Florentin M, Georgoula M, Elisaf MS. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol 2017; 10:187-200.
63. Halcox J, Misra A. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat? Metab Syndr Relat Disord 2015; 13:1-21.
64. Chang YH, Lin KD, Shin SJ, Lee YJ. Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis. Nutr Metab Cardiovasc Dis 2014; 24:1067-1073.
65. Cholesterol Treatment Trialists' (CTT) Collaborators. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125.
66. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and nondiabetic patients: meta-analysis of randomized controlled trials. BMJ 2006; 332:1115-1124.
67. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64:471-475.
68. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus-a matter for debate. Nat Rev Endocrinol 2012; 8:133-134.
69. Muscogiuri G, Sarno G, Gastaldelli A, et al. The good and bad effects of statins on insulin sensitivity and secretion. Endocr Res 2014; 39:137-143.
70. Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig 2016; 7:769-776.
71. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-362.
72. Sakamoto K, Kawamura M, Kohro T, et al., RESEARCH Study Group. Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. Plos One 2015; 10:e0138332.
73. Hiramitsu S, Miyagishima K, Ishii J, et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60:395-400.
74. Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013; 19:3107-3114.
75. Chang SH, Wu LS, Lee CH, et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study. Int J Cardiol 2015; 190:20-25.
76. Cannon CP, Blazing MA, Giugliano RP, et al., IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397.
77. Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100:46-52.
78. Saito I, Azuma K, Kakikawa T, et al. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis 2015; 14:40.
79. Steinmetz A. Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes 2003; 111:239-245.
80. Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract 2007; 61:1949-1956.
81. Keech A, Simes RJ, Barter P, et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
82. Study Group ACCORD. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
83. Elam MB, Ginsberg HN, Lovato LC, et al., ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2016. [Epub ahead of print]
84. Maki KC, Guyton JR, Orringer CE, et al. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceride-mia. J Clin Lipidol 2016; 10:905-914.
85. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
86. Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administered with low-or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardi-ovasc Drugs 2010; 10:73-84.
87. Ding Y, Li Y, Wen A. Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials. Clin Nutr 2015; 34:838-844.
88. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of nonstatin lipid lowering and antiobesity drugs on LDL subfractions in patients with mixed dyslipi-daemia. Curr Vasc Pharmacol 2010; 8:820-830.
89. Usman MH, Qamar A, Gadi R, et al. Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med 2012; 125:1026-1035.
90. Collins PD, Sattar N. Glycaemic effects of nonstatin lipid-lowering therapies. Curr Cardiol Rep 2016; 18:133.
91. Siniawski D, Santos-Gallego CG, Badimon JJ, Masson WM. Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiol 2016; 71:463-472.
92. Sandhu S, Moosavi M, Golmohammadi K, Francis GA. Colesevelam as an add-on treatment for control of dyslipidemia and hyperglycemia in type 2 diabetes. Can J Diabetes 2016; 40:112-114.
93. Athyros VG, Tziomalos K, Doumas M, et al. The effect of proprotein con-vertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins. Curr Pharm Des 2017. [Epub ahead of print]
94. Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2017; 5:97-105.
95. Karagiannis A, Tziomalos K, Anagnostis P, et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol 2010; 8:792-803.
96. Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol 2011; 31:542-552.
97. Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004; 116 (Suppl 5A):76S-88S.
98. Koulouris S, Symeonides P, Triantafyllou K, et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005; 95:1386-1388.
99. Janka HU, Nuber A, Mehnert H. Metabolic effects of ramipril treatment in hypertensive subjects with noninsulin-dependent diabetes mellitus. Arznei-mittelforschung 1990; 40:432-435.
100. Kintscher U, Marx N, Martus P, et al. Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Res Clin Pract 2010; 89:209-215.
101. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32:261-268.
102. Appel GB, Radhakrishnan J, Avram MM, et al. RENAAL Study Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26:1402-1407.
103. Derosa G, Cicero AF, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol 2005; 45:599-604.
104. Pessina AC, Ciccariello L, Perrone F, et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006; 16:137-147.
105. Tamasawa N, Matsui J, Ogawa Y, et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J Diabetes Complications 2000; 14:135-139.
106. Luque Otero M, Martell Claros N; Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005; 27:166-173.
107. Martell-Claros N, de la Cruz JJ. Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a noncomparative, open-label study. Clin Drug Investig 2011; 31:427-434.
108. Xu T, Brandmaier S, Messias AC, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care 2015; 38:1858-1867.
109. Ma J, Liu LY, Wu PH, et al. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. J Diabetes Res 2014; 2014:294017.
110. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 2012; 29:736-746.
111. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009; 58:143-148.
112. Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006; 8:197-205.
113. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metfor-min monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22:751-759.
114. Emral R, Köseoglulari O, Tonyukuk V, et al. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia. Exp Clin Endocrinol Diabetes 2005; 113:80-84.
115. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17:1093-1099.
116. Skrapari I, Perrea D, Ioannidis I, et al. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. Diabet Med 2001; 18:781-785.
117. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral antihypergly-caemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6:133-156.
118. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab 2004; 6:384-390.
119. Onishi Y, Fujisawa T, Sakaguchi K, Maeda M. Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes. Adv Ther 2006; 23:549-555.
120. Ju-Ming L, Xiao-Hui G, Xiao-Feng L, et al. Effects of nateglinide on postprandial plasma glucose excursion and metabolism of lipids in Chinese patients with type 2 diabetes: a 4-week, randomized, active-control, open-label, parallel-group, multicenter trial. Curr Med Res Opin 2012. [Epub ahead of print]
121. Nakano K, Hasegawa G, Fukui M, et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. Endocr J 2010; 57:423-430.
122. Sharma SK, Verma SH. A study of effects of pioglitazone and rosiglitazone on various parameters in patients of type-2 diabetes mellitus with special reference to lipid profile. J Assoc Physicians India 2016; 64: 24-28.
123. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphony-lurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004; 1:44-50.
124. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30:2458-2464.
125. Zeng L, Lu H, Deng H, et al. Noninferiority effects on glycemic control and b-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treat-ment. Diabetes Technol Ther 2012; 14:35-42.
126. Lindström T, Olsson AG, von Schenck H, et al. Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitus. J Intern Med 1994; 235:253-261.
127. Fukui T, Hirano T. High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without/with intensive insulin therapy. Endocr J 2012; 59:561-569.
128. Habib SS, Aslam M, Naveed AK, Razi MS. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. Saudi Med J 2006; 27:174-180.
129. Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2016; 8:26.
130. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10:73-84.
131. Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol 2014; 28:221-229.
132. Takeda H, Sasai N, Ito S, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes: analysis of the ATTAK-J Study. J Clin Med Res 2016; 8:130-140.
133. Tai H, Wang MY, Zhao YP, et al. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine (Baltimore) 2016; 95:e4541.
134. Fan M, Li Y, Zhang S. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016; 95:e2386.
135. Roca-Rodŕiguez MM, Muros de Fuentes MT, Piédrola-Maroto G, et al. Lixisenatide in patients with type 2 diabetes and obesity: beyond glycaemic control. Aten Primaria 2016. [Epub ahead of print]
136. Ojo O. The use of exenatide in managing markers of cardiovascular risk in patients with type 2 diabetes: a systematic review. Int J Environ Res Public Health 2016; 13:E941.
137. Simó R, Guerci B, Schernthaner G, et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepir-ide: results from the European exenatide study. Cardiovasc Diabetol 2015; 14:116.
138. Tokuda M, Katsuno T, Ochi F, et al. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes. Endocr J 2014; 61:365-372.
139. Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212:223-229.
140. Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14:12.
141. Bergenstal RM, Li Y, Porter TK, et al. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab 2013; 15:264-271.
142. Rizzo M, Rizvi AA, Patti AM, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 2016; 15:162.
143. Hermansen K, Bækdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab 2013; 15:1040-1048.
144. Katsiki N, Christou GA, Kiortsis DN. Liraglutide and cardiometabolic effects: more than just another antiobesity drug? Curr Vasc Pharmacol 2016; 14:76-79.
145. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 2017; 16:6.
146. Giannoglou GD, Chatzizisis YS, Zamboulis C, et al. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126:302-312.
147. Matthaei S, Bowering K, Rohwedder K, et al., Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015; 38:365-372.
148. Matthaei S, Bowering K, Rohwedder K; Study 05 Group. Durability and tolerability of dapagliflozin over 52weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab 2015; 17:1075-1084.
149. Xiong W, Xiao MY, Zhang M, Chang F. Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016; 95:e5473.
150. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagli-flozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17:294-303.
151. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30:163-175.
152. Inagaki N, Goda M, Yokota S, et al. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther 2015; 32:1085-1103.
153. Zinman B, Wanner C, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128.
154. Mamakou V, Eleftheriadou I, Katsiki N, et al. Antidiabetic drugs as antihyper-tensives: new data on the horizon. Expert Opin Pharmacother 2017; In press.
155. Athyros VG, Katsiki N, Karagiannis A. Editorial: can glucagon like peptide 1 (GLP1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes? Curr Vasc Pharmacol 2016; 14:494-497.
156. Athyros VG, Katsiki N, Tentolouris N. Editorial: do some glucagon-like-peptide-1 receptor agonists (GLP-1 RA) reduce macrovascular complications of type 2 diabetes mellitus a commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial. Curr Vasc Pharmacol 2016; 14:469-473.
157. Katsiki N, Athyros VG, Mikhailidis DP. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications 2017; 31:521-522.
158. Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management. Curr Pharm Des 2017; Jan 13. [Epub ahead of print]
159. Marso SP, Bain SC, Consoli A, et al., SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834-1844.
160. Marso SP, Daniels GH, Brown-Frandsen K, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311-322.